Anthony Chin-Ki Ng Selected Research

Length of Stay

1/2020

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony Chin-Ki Ng Research Topics

Disease

6	COVID-19 01/2021 - 01/2020
3	Infections 11/2021 - 01/2020
1	Reinfection 11/2021
1	Virus Diseases (Viral Diseases) 01/2021
1	Hepatitis 01/2020

Drug/Important Bio-Agent (IBA)

2	Immunoglobulin G (IgG)IBA 11/2021 - 09/2020
2	EnzymesIBA 09/2020 - 01/2020
1	C-Reactive ProteinIBA 11/2021
1	VaccinesIBA 11/2021
1	LipidsIBA 01/2021
1	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2021
1	SphingomyelinsIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 11/2020
1	Lopinavir FDA Link 01/2020
1	AntibodiesIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	InterferonsIBA 01/2020
1	Ribavirin (Virazole)FDA LinkGeneric 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	ChemokinesIBA 01/2020
1	Ritonavir (Norvir)FDA Link 01/2020
1	Interferon beta-1b (Betaseron)FDA Link 01/2020

Therapy/Procedure

1	Length of Stay 01/2020
1	Therapeutics 01/2020